Close

Boston Scientifics PFA system achieves efficacy and safety endpoints

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

Boston Scientific has announced the achievement of primary efficacy and safety endpoints in the ADVENT Study of the FARAPULSE Pulsed Field Ablation (PFA) System.

FARAPULSE is a nonthermal treatment, which selectively applies electric fields for ablating heart tissue in patients with atrial fibrillation (AF).

The pivotal, randomised clinical study compared the efficacy and safety of the system versus standard-of-care ablation, either cryoablation or radiofrequency, to treat patients with paroxysmal, or intermittent, AF.

Over the course of 12 months, the data indicated that the system was as effective as standard-of-care treatments, even though most physicians had only worked with thermal ablation in the past.

The prospective, multicentre trial included 607 US patients with paroxysmal AF who had earlier been unsuccessfully treated with a minimum of one anti-arrhythmic drug.

Boston Scientific global chief medical officer and senior vice-president Kenneth Stein said: “These data underscore the superior procedural efficiency of this novel technology, and real-world use continues to yield strong safety and efficacy outcomes.

“The performance of the FARAPULSE PFA System in this trial is an encouraging sign of the potential utilisation of the device in the US and we look forward to further studying the system for the treatment of patients with persistent AF in the ADVANTAGE AF clinical trial, which began enrolment earlier this year.”

 

In 2021, the company received CE Mark for the FARAPULSE PFA System. So far, it has been used to treat over 25,000 patients across the globe.

 

Latest stories

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back